Gilead
WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19
October 26, 2020Sales and Marketing COVID, COVID-19, Gilead, coronavirus
The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir …
FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
October 23, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir
The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …
Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients
October 22, 2020Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …
European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit
October 19, 2020Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir
As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …
Gilead to meet rising remdesivir demand in Europe with new supply deal
October 8, 2020Manufacturing and Production COVID-19, Europe, Gilead
The European Commission (EC) has signed a new joint procurement agreement (JPA) with pharma firm Gilead to improve access to …
Japan approves Gilead and Eisai’s Jyseleca for rheumatoid arthritis
September 25, 2020Medical Communications, Sales and Marketing Eisai, Gilead, Japan, Jyseleca
Gilead and Eisai have secured approval for their oral JAK1 preferential inhibitor Jyseleca (filgotinib) from the Japanese Ministry of Health, …
Gilead agrees to pay $97 million to settle Medicare kickbacks case
September 24, 2020Business Services Gilead, Medicare, drugs, kickbacks
Gilead has agreed to pay $97 million to resolve claims from the US Government that it used an independent charity …
Gilead scoops up Immunomedics in deal worth $21 billion
September 14, 2020Sales and Marketing Gilead, Immunomedics, acquisition, pharma
The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …
Gilead and Jounce Therapeutics forge immuno-oncology partnership worth a potential $700m+
September 2, 2020Research and Development, Sales and Marketing Gilead, jounce, oncology, pharma
Gilead and Jounce Therapeutics have come together in a new immuno-oncology partnership potentially worth over $700 million. The primary drive …
Gilead says FDA could expand eligibility of coronavirus patients for remdesivir
August 24, 2020Sales and Marketing FDA, Gilead
The FDA could expand its Emergency Use Authorization (EUA) for Gilead’s remdesivir for treating coronavirus patients, according to Gilead.
FDA turns down Gilead’s JAK inhibitor filgotinib in rheumatoid arthritis, endangering 2020 approval hopes
August 20, 2020Research and Development, Sales and Marketing FDA, Gilead, filgotinib
Gilead’s JAK inhibitor filgotinib has been unexpectedly knocked back by the FDA as a therapy to treat moderately to severely …
Racial minority groups are not adequately represented in COVID-19 clinical studies, research argues
August 12, 2020Research and Development COVID-19, Gilead, pharma, remdesivir
New research has warned that minority groups and people of colour are underrepresented in current trials for COVID-19 therapies, despite …
Gilead applies for FDA approval to treat coronavirus patients with remdesivir
August 11, 2020Manufacturing and Production COVID-19, Gilead, coronavirus
Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients. The drug would go under …
Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma
July 27, 2020Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma
Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …
Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
July 20, 2020Sales and Marketing COVID-19, Gilead, India, Mylan, generic, remdesivir
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for the treatment of patients with …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
